The Medical Letter website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more      
The Medical Letter on Drugs and Therapeutics
Issue 1545
Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia; Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV; Ertugliflozin for Type 2 Diabetes; Nebulized Glycopyrrolate (Lonhala Magnair) for COPD; Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (online only); Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
The full issue is available to subscribers Subscriber Login   
Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia

The FDA has approved deutetrabenazine (Austedo – Teva), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of chorea associated with Huntington's disease and, more recently, for treatment of tardive dyskinesia in adults. It is the second VMAT2 inhibitor to be approved for each of these indications; tetrabenazine (Xenazine, and generics) was approved earlier for Huntington's chorea1 and valbenazine (Ingrezza) was recently approved for treatment of adults with tardive dyskinesia.2

HUNTINGTON'S DISEASE — Huntington's disease is an autosomal dominant, progressive neurodegenerative disorder caused by mutations in the huntingtin (HTT) gene that encodes the huntingtin protein. No available treatment slows progression of the disease, but symptomatic treatment of depression, anxiety, cognitive impairment, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1545
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35